A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-16

Study Completion Date

2024-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the study is to learn what happens to different oral formulations of tedizolid phosphate (MK-1986) in a healthy person's body over time. Researchers want to know if there is a difference in the oral formulations absorption and elimination from the healthy persons body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

NCT02477514

Skin Diseases, Bacterial

COMPLETED PHASE1

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

NCT07258173

Trichuris Infection Trichuris

NOT_YET_RECRUITING PHASE2

Bioavailability of Levoketoconazole and Ketoconazole Tablets

NCT04212000

Healthy

COMPLETED PHASE1

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

NCT04486313

COVID-19

COMPLETED PHASE3

Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions

NCT00805155

Healthy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tedizolid Phosphate Oral Formulation 1 (Reference)

Participants will receive oral Formulation 1 (Reference).

Group Type EXPERIMENTAL

Tedizolid Phosphate Oral Formulation 1 (Reference)

Intervention Type DRUG

Formulation 1 (FM1) powder for oral suspension.

Tedizolid Phosphate Oral Formulation 2 (Test)

Participants will receive oral Formulation 2 (Test).

Group Type EXPERIMENTAL

Tedizolid Phosphate Oral Formulation 2 (Test)

Intervention Type DRUG

Formulation 2 (FM2) powder for oral suspension.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tedizolid Phosphate Oral Formulation 1 (Reference)

Formulation 1 (FM1) powder for oral suspension.

Intervention Type DRUG

Tedizolid Phosphate Oral Formulation 2 (Test)

Formulation 2 (FM2) powder for oral suspension.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2

Exclusion Criteria

* Has a history of or presence of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome), or uncorrected hypokalemia or hypomagnesemia
* Has a history of clostridium difficile-associated diarrhea

Minimum Eligible Age

19 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes